Emergent BioSolutions Inc.
EBSEmergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Drugs in Pipeline
11
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
HuMax-CD4
T Cell Lymphoma
AV7909
Anthrax
ACAM2000
Smallpox Vaccine Adverse Reaction
BioThrax
Anthrax
ACAM2000 Smallpox Vaccine
Smallpox
AIGIV 3.5 mg/kg
Anthrax
Ciprofloxacin 500Mg Tablet
Anthrax
Vaccinia virus: ACAM2000 smallpox vaccine
Smallpox
Dose of 5.0 x 10^9 CFU (Cohort 1)
Typhoid
Ciprofloxacin
Anthrax
FLU-IGIV
Influenza A H3N2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HuMax-CD4 | Phase 3 | T Cell Lymphoma | - | - |
AV7909 | Phase 3 | Anthrax | - | - |
ACAM2000 | Phase 3 | Smallpox Vaccine Adverse Reaction | - | - |
BioThrax | Phase 3 | Anthrax | - | - |
ACAM2000 Smallpox Vaccine | Phase 2 | Smallpox | - | - |
AIGIV 3.5 mg/kg | Phase 2 | Anthrax | - | - |
Ciprofloxacin 500Mg Tablet | Phase 2 | Anthrax | - | - |
Vaccinia virus: ACAM2000 smallpox vaccine | Phase 2 | Smallpox | - | - |
Dose of 5.0 x 10^9 CFU (Cohort 1) | Phase 2 | Typhoid | - | - |
Ciprofloxacin | Phase 2 | Anthrax | - | - |
FLU-IGIV | Phase 2 | Influenza A H3N2 | - | - |